ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · Real-Time Price · USD
11.08
-0.13 (-1.16%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.

The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.

It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.

In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting.

It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC.

The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.

ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc.
ClearPoint Neuro logo
Country United States
Founded 1998
Industry Medical Devices
Sector Healthcare
Employees 172
CEO Joseph Burnett

Contact Details

Address:
120 S. Sierra Avenue, Suite 100
Solana Beach, California 92075
United States
Phone 888 287 9109
Website clearpointneuro.com

Stock Details

Ticker Symbol CLPT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001285550
CUSIP Number 18507C103
ISIN Number US18507C1036
Employer ID 58-2394628
SIC Code 3841

Key Executives

Name Position
Joseph Michael Burnett President, Chief Executive Officer and Director
Danilo D'Alessandro Chief Financial Officer
Jeremy L. Stigall Chief Business Officer
Ellisa Cholapranee J.D. General Counsel and Secretary
Robert C. Korn Senior Vice President of Sales and Business Development
Dr. Paul S. Larson FAANS, M.D. Chief Medical Officer
Mary McNamara-Cullinane RAC Senior Vice President of Regulatory Affairs
Megan Faulkenberry Senior Vice President of Quality

Latest SEC Filings

Date Type Title
Apr 23, 2026 ARS Filing
Apr 23, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 20, 2026 SCHEDULE 13G/A Filing
Apr 10, 2026 DEF 14A Other definitive proxy statements
Mar 26, 2026 SCHEDULE 13G/A Filing
Mar 17, 2026 10-K Annual Report
Mar 17, 2026 8-K Current Report
Mar 13, 2026 SCHEDULE 13G Filing
Feb 25, 2026 144 Filing
Feb 20, 2026 144/A Filing